The human papillomavirus (HPV) vaccine market was valued at USD 5.22 Billion in 2024 driven by the rising incidence of HPV-related disease and technological advancements in vaccine technology across the 8 major markets. It is expected to grow at a CAGR of 11.60% during the forecast period 2025-2034 and attain a market value of USD 15.64 Billion by 2034.
Base Year
Historical Period
Forecast Period
In the United States, around 47,984 new cases of cancer related to human papillomavirus (HPV) are identified annually, with 26,280 cases in females and 21,704 in males. This indicates the increasing prevalence of HPV-related diseases, which is expected to fuel the market demand.
In September 2024, Merck announced positive top-line results from a Phase 3 trial evaluating the efficacy and safety of the 9-valent Human Papillomavirus (HPV) vaccine GARDASIL®9 in Japanese males aged 16 to 26. The growth in such clinical trials is a significant market trend.
The FDA granted Breakthrough Therapy Designation in September 2023 for INO -3107, which targets recurrent respiratory papillomatosis, a rare disease caused by HPV-6 and/or HPV-11. The robust regulatory support from health authorities like the FDA is likely to elevate the market value.
Compound Annual Growth Rate
11.6%
Value in USD Billion
2025-2034
Human Papillomavirus (HPV) Vaccine Market Outlook
*this image is indicative*
HPV vaccine is a preventative measure against the Human Papillomavirus (HPV), a common sexually transmitted infection that can cause genital warts and various forms of cancer. HPV is spread through sexual intercourse and is classified into high-risk and low-risk strains. High-risk strains are linked to several types of cancer, such as cervical cancer. Most HPV infections show no symptoms and resolve without treatment, but long-lasting infections can eventually result in cancer. Routine screening and vaccination are crucial techniques for handling health risks associated with HPV, supported by major health organizations such as the WHO.
The growing use of vaccines to help lower the risk of cervical and other cancers caused by high-risk HPV strains is propelling the demand for the human papillomavirus (HPV) vaccine market. HPV vaccine assists the immune system in combatting the disease before it can be harmful, thereby reducing the chances of developing genital warts and cancers. The market is also witnessing increased vaccination efforts that target preteens and young adults to achieve the greatest impact in halting the spread of HPV and enhancing overall public health. Moreover, the rising advancements in vaccine formulations and the growing focus on preventive healthcare are likely to impact the market dynamics.
Rising Incidence of HPV-Related Disease Spurs Market Growth
The growth in the HPV vaccine market is mainly being fueled by the rising cases of HPV-linked illnesses such as cervical, anal, and oropharyngeal cancers. In the United States, around 47,984 new cases of cancer related to human papillomavirus (HPV) are identified annually, with 26,280 cases in females and 21,704 in males. HPV causes about 37,800 of these cancers, with cervical cancer prevalent among women and oropharyngeal cancers in men. Further, as a common sexually transmitted infection (STI), HPV poses a significant risk of developing cancer. This has prompted global health organizations such as the WHO and CDC to advocate for widespread vaccination as a preventive measure, which is poised to boost market growth.
Advancements in Vaccines Drive Increased Demand in the Human Papillomavirus (HPV) Vaccine Market
Advancements in HPV vaccine technology, including Gardasil 9 which guards against nine strains, have increased their ability to prevent different types of cancers. In September 2024, Merck announced positive top-line results from a Phase 3 trial evaluating the efficacy and safety of its 9-valent Human Papillomavirus (HPV) vaccine GARDASIL®9 in Japanese males aged 16 to 26. Continuing studies on single-shot vaccines and mixed vaccinations seek to streamline immunization procedures and improve adherence, particularly in areas with limited resources. Thus, the market is ready for further expansion as healthcare providers and governments implement these advanced vaccines to address the worldwide HPV disease burden.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
The EMR’s report titled “Human Papillomavirus (HPV) Vaccine Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Market Breakup by Indication
Market Breakup by Route of Administration
Market Breakup by Distribution Channel
Market Breakup by Region
Market Segmentation Based on the Type Holds Substantial Market Share
Based on type, the market is segmented into bivalent and polyvalent. Among these, the polyvalent segment is expected to dominate the market due to its broader protection against cervical, anal, and other cancers. Polyvalent vaccines target multiple HPV strains including high-risk ones. Higher demand for these vaccines is seen in regions with government-endorsed vaccination programs. With growing awareness of HPV's role in cancer, polyvalent vaccines are preferred for their comprehensive coverage, appealing to healthcare providers and public health programs.
The Distribution Channel Segment is Expected to Propel Human Papillomavirus (HPV) Vaccine Market Demand
The market segmentation by distribution channels includes hospital and retail pharmacies, government suppliers, and others. Out of these, hospital and retail pharmacies are expected to dominate the market due to their accessibility and availability of HPV vaccines. Hospitals play a crucial role in vaccination programs, especially for adolescents, while retail pharmacies offer convenient access without appointments.
Based on region, the market report covers the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and India.
The United States is expected to dominate the market powered by its extensive public health campaigns and government-supported vaccination programs. Polyvalent vaccines are widely used in the region, with broad availability in pharmacies and hospitals, along with insurance coverage contributing to their dominance in the market.
EU-4 and the United Kingdom are also poised to have significant human papillomavirus (HPV) vaccine market share supported by the acceptance of national HPV vaccination and the implementation of school-based vaccination programs. The free HPV vaccines provided by the UK's National Health Service (NHS) are further resulting in elevated vaccination rates among adolescents.
The market in the Japan and India region is rapidly expanding. Japan has seen a resurgence in the HPV vaccine market after public vaccination recommendations were reinstated following a temporary suspension due to safety worries. In India, the government's national immunization campaign, with support from GAVI (The Global Alliance for Vaccines and Immunization), is increasing HPV vaccination coverage despite challenges such as low awareness and limited healthcare access in rural areas.
The key features of the market report include patent analysis, grant analysis, clinical trials analysis as well as strategic initiatives including recent partnerships and collaborations by the leading players. The major companies in the market are as follows:
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company focuses on the discovery, development, manufacturing, and marketing of prescription medicines, biologic therapies, and vaccines.
The Serum Institute of India, based in Pune, is a leading biotechnology company and the largest vaccine manufacturer globally. In partnership with the Indian government, they have developed Cervavac, India's first HPV vaccine. This initiative aims to prevent the deaths of 70,000 women annually from cervical cancer in the country.
Inovio Pharmaceuticals is an American biotech company specializing in synthetic DNA products for cancer and infectious diseases. The FDA granted Breakthrough Therapy Designation in September 2023 for INO -3107, which targets recurrent respiratory papillomatosis, a rare disease caused by HPV-6 and/or HPV-11. Inovio aims to develop DNA medicines for HPV-related conditions, cancer, and infectious diseases to improve patient outcomes.
Walvax Biotechnology Co Ltd is a company that develops vaccines and blood products, including the haemophilus influenza vaccine for diseases like meningitis. They also offer drugs for pneumonia, septicemia, cellulitis, arthritis, and epiglottitis. In August 2024, they announced that the World Health Organization has pre-qualified their Walrinvax™ HPV vaccine, showing that it meets WHO standards for safety, efficacy, and quality control, as well as compliance with WHO GMP requirements.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other players in the market are GlaxoSmithKline plc, Johnson & Johnson Services Inc., Bavarian Nordic A/S, Bharat Biotech International Limited (BBIL), Sanofi SA, and Beijing Wantai Biolog Pha Ent Co Ltd.
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
In 2024, the global human papillomavirus (HPV) vaccine market attained a value of nearly USD 5.22 Billion.
The market is assessed to grow at a CAGR of 11.60% between 2025 and 2034.
The market is estimated to witness healthy growth in the forecast period of 2025-2034 to reach almost USD 15.64 Billion by 2034.
The major market drivers are the growing awareness regarding human papillomavirus, the rising incidences of HPV-associated cancers, the increasing healthcare facilities.
The key market trends guiding the growth of the market include the introduction of various government initiatives to boost HPV vaccination, the growing incidences of HPV-related malignancies, and developing healthcare infrastructure.
The major regions in the market are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
The various types of human papillomavirus virus (HPV) vaccine in the market are bivalent and polyvalent.
The different distribution channel of human papillomavirus (HPV) vaccine include hospital and retail pharmacies and government suppliers, among others.
The significant indications of human papillomavirus (HPV) vaccine in the market are genital warts and HPV associated cancer.
The major diseases of human papillomavirus (HPV) vaccine, include systemic human papillomavirus vaccine and localised human papillomavirus vaccine.
The major players in the market are Merck & Co., Inc., GlaxoSmithKline plc., Johnson & Johnson Services, Inc., Serum Institute of India Pvt. Ltd., and Bavarian Nordic A/S, among others.
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Indication |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
